Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $44.9M | $83.0M | $52.6M | $49.9M | $76.6M | $80.8M | $94.8M |
| Cost of revenue | $1.1M | $35.5M | $74.0M | $43.1M | $41.0M | $62.7M | $68.2M | $77.5M |
| Gross profit | $904.8K | $9.4M | $9.1M | $9.6M | $8.9M | $13.9M | $12.6M | $17.3M |
| Gross margin | 46.1% | 21.0% | 10.9% | 18.2% | 17.9% | 18.1% | 15.6% | 18.2% |
| R&D | $275.8K | $2.9M | $492.0K | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$3.3M | −$9.7M | −$16.0M | −$5.0M | −$17.8M | −$20.9M | $6.3M | −$2.6M |
| EBITDA | −$1.2M | −$6.3M | −$7.1M | −$3.4M | −$3.0M | −$3.5M | $8.9M | $668.0K |
| Net income | −$4.0M | −$10.8M | −$19.4M | −$12.9M | −$20.0M | −$24.4M | −$49.4M | −$11.1M |
| Net margin | -202.6% | -24.0% | -23.4% | -24.6% | -40.1% | -31.9% | -61.1% | -11.7% |
| EPS (diluted) | -2505.30 | -6272.14 | -6671.13 | -3530.31 | -4230.90 | -3779.31 | -2290.24 | -192.75 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds DYNE.
No tracked institution reports a position in DYNE as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2023-07-26 | $3.6957 | 2023-07-25 |
No one on the platform has traded DYNE yet.
| $287788 |
| — |
| MCCXMCX Technologies Corporation | $0.01 | -48.94% | $245114 | — |
| MRRYFMary Agrotechnologies Inc. | $0.04 | +0.00% | $2M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
@ZacksResearch Exon skippers like $DYNE DYNE-251 or Avidity/Novartis $RNA $NVS del-zeta, and drugs designed to improve muscle mass and retrograde signaling like $KROS KER-065 or $SRRK's apitegromab are complementary and not competing. Ultimately they should be tested in combination once they show efficacy as single therapies.
View on StockTwits ↗$DYNE Gallant Capital Partners Invests in Cybersecurity Firms DynTek and rSolutions to Support Growth and Innovation https://www.stocktitan.net/news/DYNE/gallant-capital-partners-invests-in-cybersecurity-firms-dyn-tek-and-nz9at2wmkp7n.html
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.